Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- IMUX
- Price
- 0.92
- Stock movement up
- +0.00 (0.47%)
- Company name
- Immunic Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 110.34M
- Ent value
- 105.41M
- Price/Sales
- 967.87
- Price/Book
- 10.51
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -26.01%
- 1 year return (CAGR)
- -4.12%
- 3 year return (CAGR)
- -23.26%
- 5 year return (CAGR)
- -46.28%
- 10 year return (CAGR)
- -44.90%
Last updated: 2026-03-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IMUX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 967.87 |
| Price to Book | 10.51 |
| EV to Sales | 924.65 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 120.28M |
| EPS (TTM) | -0.06 |
| FCF per share (TTM) | -0.06 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -128.00K |
| Operating income (TTM) | -103.23M |
| Net income (TTM) | -97.17M |
| EPS (TTM) | -0.06 |
| EPS (1y forward) | -0.39 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.48M |
| Net receivables | 4.12M |
| Total current assets | 22.87M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 24.05M |
| Accounts payable | 10.14M |
| Short/Current long term debt | 684.00K |
| Total current liabilities | 30.62M |
| Total liabilities | 30.73M |
| Shareholder's equity | -6.67M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -85.81M |
| Capital expenditures (TTM) | 161.00K |
| Free cash flow (TTM) | -85.97M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -404.01% |
| Return on Invested Capital | 1566.53% |
| Cash Return on Invested Capital | 1385.89% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.93 |
| Daily high | 0.96 |
| Daily low | 0.85 |
| Daily Volume | 6.05M |
| All-time high | 1332.40 |
| 1y analyst estimate | 4.50 |
| Beta | 1.48 |
| EPS (TTM) | -0.06 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 19 Feb 2026 |
Downside potential
Loading...
Downside potential data
| IMUX | S&P500 | |
| Current price drop from All-time high | -99.93% | -1.82% |
| Highest price drop | -99.96% | -56.47% |
| Date of highest drop | 30 Dec 2025 | 9 Mar 2009 |
| Avg drop from high | -87.03% | -10.84% |
| Avg time to new high | 175 days | 12 days |
| Max time to new high | 2936 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
110.34M
Marketcap category
Small-cap
Description
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Employees
90
Website
Investor relations
-
SEC filings
CEO
Daniel Vitt
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page